Research confirms benefits of side-actuated nasal spray
Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.
The side-actuated nasal spray consists of a standard actuator coupled with a customisable shell and cap.
The research, carried out in the UK last November involving 10 regular nasal spray users, as well as six doctors (GPs and ENT specialists), showed that the side-actuated delivery device has the three advantages mentioned above.
Patients also thought a slightly longer nozzle would improve the placement of the device in the nostril when the device is actuated, and Valois will further investigate this.
The company says new user research will be carried out in the US in the coming months to confirm the results of the current study.
You may also like
Research & Development
Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity
Read moreThe researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
Research & Development
Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss
Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory
Johnson & Johnson files FDA application for IMAAVY in wAIHA
Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development
Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies
Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Drug Delivery
AI might find the molecule, but delivery decides whether it becomes a medicine
As the pharmaceutical industry scales AI-driven discovery at unprecedented speed, will the early integration of formulation and manufacturability determine which computationally promising molecules become deliverable medicines?
Research & Development
SPARK THE MIDLANDS backs Aston University anti-cancer bone paste collaboration
A collaboration between Aston University and Royal Orthopaedic Hospital NHS Foundation Trust has secured support from SPARK THE MIDLANDS to advance a minimally invasive gallium-doped injectable paste for treating primary and metastatic bone cancer
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Landmark NHS‑Galleri trial cuts Stage IV cancers and boosts early detection across England
NHS‑Galleri trial shows multi‑cancer blood test sharply reduces late‑stage diagnoses and boosts early detection—possibly signalling a structural change in cancer drug demand, supply chain planning and long-term oncology production strategy